**CLAIMS**

What is claimed is:

1. An oral drug dosage form configured to release a drug at a desired location in the colon of an individual, the oral drug dosage form comprising:

a drug component comprising an erodible material admixed with the drug; and

a delay component not admixed with the drug,

wherein the delay component is configured to prevent release of the drug from the drug component until the oral drug dosage form reaches the colon of the individual following administration, and

wherein the delay component comprises:

a pH-based enteric member comprising an erodible material configured to erode at or above a pre-determined pH value.

2. The oral drug dosage form of claim 1, wherein the delay component further comprises an erodible delay member, and wherein the oral drug dosage form is configured such that the pH-based enteric member erodes prior to the erodible delay member; or

optionally wherein the pH-based enteric member prevents erosion, at least in part, of the erodible delay member, and the erodible delay member prevents erosion, at least in part, of the drug component.

3. The oral drug dosage form of any one of claims 1-3, further comprising a second drug or

optionally wherein the second drug is admixed with the drug component; or

optionally further comprising a second drug component comprising an erodible material admixed with the second drug, wherein the delay component is configured to prevent release of the second drug from the second drug component until the oral drug dosage form reaches the colon of the individual following administration.

4. The oral drug dosage form of claim 3, wherein the delay component comprises a second erodible delay member, wherein the oral drug dosage form is configured such that the pH-based enteric member erodes prior to the erodible delay member, the erodible delay member erodes prior to the second drug component, the second drug component erodes prior to the second erodible delay member, and the second erodible delay member erodes prior to the drug component; or

optionally wherein the pH-based enteric member prevents erosion, at least in part, of the erodible delay member, the erodible delay member prevents erosion, at least in part, of the second drug component, the second drug component prevents erosion, at least in part, of the second erodible delay member, and the second erodible delay member prevents erosion, at least in part, of the drug component.

5. The oral drug dosage form of claim 2, further comprising a bacterial degradation moiety; or

optionally wherein the bacterial degradation moiety is admixed with the erodible material of the erodible delay member; or

optionaly wherein the bacterial degradation moiety is admixed with the drug component.

6. The oral drug dosage form of claim 5, wherein the delay component further comprises a bacterial degradation member comprising an erodible material admixed with the bacterial degradation moiety, wherein the oral drug dosage form is configured such that the pH-based enteric member erodes prior to the erodible delay member, the erodible delay member erodes prior to the bacterial degradation member, and the bacterial degradation member erodes prior to the drug component; or

optionally wherein the pH-based enteric member prevents erosion, at least in part, of the erodible delay member, the erodible delay member prevents erosion, at least in part, of the bacterial degradation member, and the bacterial degradation member prevents erosion, at least in part, of the drug component; or

optionally wherein the bacterial degradation moiety comprises one or more saccharides.

7. The oral drug dosage form of claim 6, wherein the bacterial degradation member is a layer, and wherein the layer has a thickness, as based on the direction of erosion, of about 0.1 mm to about 5 mm; or

optionally wherein the bacterial degradation member comprises a surface area exposed to a gastrointestinal fluid in the individual of about 10 $mm^2$ to about 400 $mm^2$ ; or

optionally wherein the drug component comprises a top surface, a bottom surface, and one or more side surfaces, and wherein the drug component is embedded in the delay component such that erosion of the delay component, or an aspect thereof, exposes at least two surfaces of any of the top surface, the bottom surface, or at least one of the one or more side surfaces to gastrointestinal fluid of the individual.

8. The oral drug dosage form of claim 1, wherein the oral drug dosage form further comprises a shell not admixed with the drug, wherein the oral drug dosage form is configured such that the shell, or a portion thereof, and the delay member prevent erosion of the drug component.

9. The oral drug dosage form of claim 1, further comprising a protease scavenger and/ or a protease inhibitor; or

optionally wherein the protease scavenger or the protease inhibitor is admixed with the delay component, or a portion thereof; or

optionally wherein the protease scavenger or the protease inhibitor is admixed in the erodible material of the erodible delay member.

10. The oral drug dosage form of claim 2, wherein the erodible delay member prevents release of the drug from the drug component for at least about 10 minutes following contact of the erodible delay member to a gastrointestinal fluid in the individual or

optionally wherein the erodible delay member is a layer having a thickness, as based on the direction of erosion, of about 0.1 mm to about 5 mm; or

optionally wherein the erodible delay member comprises a surface area exposed to a gastrointestinal fluid in the individual of about 10 $mm^2$ to about 400 $mm^2$.

11. The oral drug dosage form of claim 1, wherein the drug component is a controlled-release drug component; or

optionally wherein the drug component is a sustained-release drug component; or

optionally wherein the drug component is an immediate-release drug component; or

optionally wherein the drug component is configured to provide a drug release profile comprising a zero-order release profile, first-order release profile, delayed release profile, pulsed release profile, iterative pulsed release profile, immediate release profile, or sustained release profile, or a combination thereof.

12. The oral drug dosage form of claim 1, wherein the weight ratio of the drug component to the delay component is about 1:10 to about 10:1; or

optionally wherein the drug component is a layer having a thickness, as based on the direction of erosion, of about 0.1 mm to about 5 mm; or

optionally herein the drug component comprises a surface area exposed to a gastrointestinal fluid in the individual of about 10 $mm^2$ to about 400 $mm^2$.

13. The oral drug dosage form of claim 1, further comprising a second pH-based enteric member; or

optionally wherein the pH-based enteric member erodes from the oral drug dosage form at or above a pH value of about 5.5, or a portion thereof; or

optionally wherein the second pH-based enteric member erodes from the oral drug dosage form at or above a pH value of about 6.8, or a portion thereof.

14. Use of an oral drug dosage form in the manufacture of a medicament for the treatment of ulcerative colitis wherein the oral drug dosage form is configured to release a drug at a desired gastrointestinal location in an individual by a method,

wherein the oral drug dosage form comprises:

a drug component comprising:

a first erodible material admixed with a drug, and

a first erodible tracking stripe; and

a shell comprising a second tracking stripe;

a delay component not admixed with the drug, the delay component comprising:

a pH-based enteric member configured to erode at or above a pre-determined pH value,

wherein the pH based enteric member comprises a third erodible tracking stripe; and

an erodible delay member comprising a second erodible material,

wherein the erodible delay member comprises a fourth erodible tracking stripe,

wherein the pH-based enteric member, alone or in combination with the shell, prevents erosion of the erodible delay member, and

wherein the erodible delay member, alone or in combination with the shell, prevents erosion of the drug component,

wherein the method comprising:

(a) the oral drug dosage form is to be administered to an individual;

(b) imaging the individual over a time course to obtain a location of the oral drug dosage form and a status of the first erodible tracking stripe, the second erodible tracking stripe, the third erodible tracking stripe, and the fourth tracking stripe; and

(c) adjusting the drug component and/ or delay component and/or shell, or portion thereof, based on the location and the status of the first erodible tracking stripe, the second erodible tracking stripe, the third erodible tracking stripe, and the fourth track stripe to design the oral drug dosage form configured to release the drug at a desired gastrointestinal location in the individual.

15. Use of an oral drug dosage form in the manufacture of a medicament for the treatment of ulcerative colitis wherein the oral drug dosage form is configured to release a drug at a desired gastrointestinal location in an individual by a method,

wherein the oral drug dosage form comprises:

a drug component comprising a first erodible material admixed with a drug; and

a delay component not admixed with the drug, the delay component comprising:

a pH-based enteric member configured to erode at or above a pre-determined pH value; and

an erodible delay member comprising a second erodible material,

wherein the pH-based enteric member prevents erosion of the erodible delay member, and

wherein the erodible delay member prevents erosion of the drug component,

wherein the oral drug dosage form comprises at least one tracking stripe positioned in a component thereof,

wherein the method comprising:

(a) the oral drug dosage form is to be administered to an individual;

(b) imaging the individual over a time course to obtain a location of the oral drug dosage form and a status of the at least one tracking stripe; and

(c) adjusting the drug component and/ or delay component, or portion thereof, based on the location and the status of the at least one tracking stripe, to design the oral drug dosage form configured to release the drug at a desired gastrointestinal location in the individual.